Atossa Genetics (NASDAQ:ATOS) Price Target & New Coverage by Maxim Group

Analysts at Maxim Group started coverage on shares of Atossa Genetics (NASDAQ:ATOS) in an analyst note revealed to investors on 26 January. The broker set Buy rating on the $4.35 million market cap company.

The new coverage is welcomed by stock traders, as NASDAQ:ATOS is right now trading 2.62% higher at $1.12 as of 12:06 PM New York time. Atossa Genetics shares have [From2] 0% over the last 200 days, while the Standard & Poor’s 500 index has increased 6.00% in the same time.

Atossa Genetics (NASDAQ:ATOS) Profile

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer.

Atossa Genetics (NASDAQ:ATOS) traded up 2.62% on 26 January, hitting $1.12. A total of shares of the company’s stock traded hands. This is down from average of 79,522 shares. Atossa Genetics has a 52 week low of $0.98 and a 52 week high of $6.3. The company has a market cap of $4.35M and a P/E ratio of 0.

Get the latest Atossa Genetics (NASDAQ:ATOS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Atossa Genetics (NASDAQ:ATOS) Now Covered by Analysts at Maxim Group. The Target Price is $2.0 appeared first on Octafinance.